Jeffrey E Rubnitz MD

Pediatric Hematology & Oncology•Memphis, TN

Director, Leukemia/Lymphoma Division, St. Jude Children's Research Hospital

St. Jude Children's Research Hospital262 Danny Thomas PlaceMemphis, TN 38105

Dr. Rubnitz is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rubnitz's full profile Already have an account?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 1991 - 1994
Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 1988 - 1991
University of California San Diego School of MedicineClass of 1988

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1989 - Present
TN State Medical License 1995 - 2028
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
COMPLETED
PHASE3
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
COMPLETED
PHASE3
Natural Killer (NK) Cell Transplantation for AML
COMPLETED
NA

Publications & Presentations

PubMed

Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloi...
Katelyn P Daniels, Stanley B Pounds, Huiyun Wu, Lei Wang, Thomas B Alexander
The Lancet. Haematology. 2026-08-01
Traumatic lumbar puncture at diagnosis in children and adolescents with acute lymphoblastic leukemia.
Hiroto Inaba, Elena Varotto, Yinmei Zhou, John K Choi, Jeffery M Klco
Leukemia. 2026-07-31
DNA Methylation of Pharmacologic and Leukemia-Related Genes Predicts Clinical Outcomes in Pediatric Acute Myeloid Leukemia.
Naifah Alshameri, Francisco Marchi, Xueyuan Cao, Jeffrey E Rubnitz, Raul C Ribeiro
Cancers. 2026-07-31

Abstracts/Posters

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid LeukemiaClinically Relevant Ab...
Jeffrey Rubnitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Jeffrey Rubnitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome
Jeffrey Rubnitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Using Pharmacogenomics to Guide Induction May Reduce Racial Disparities in Pediatric AMLDecember 9th, 2023
Drug Offers Promising Approach to Improve Outcome for Children with High-Risk LeukemiaFebruary 10th, 2016
Drug Offers Promising Approach to Improve Outcome for Children with High-Risk LeukemiaFebruary 10th, 2016